What is the Coombs test (Antiglobulin test)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The Coombs test is a crucial diagnostic tool used to detect antibodies or complement proteins attached to the surface of red blood cells, and it should be considered in patients with chronic lymphocytic leukemia, non-Hodgkin lymphoma, and in patients with a history of autoimmune disease, as recommended by the most recent guidelines 1.

Introduction to the Coombs Test

The Coombs test is a blood test that plays a significant role in identifying the presence of antibodies or complement proteins attached to the surface of red blood cells. There are two main types of Coombs tests: the direct Coombs test (DAT) and the indirect Coombs test (IAT). The DAT identifies antibodies already bound to red blood cells, while the IAT detects free antibodies in the serum that can bind to red blood cells.

Clinical Applications of the Coombs Test

The Coombs test is commonly used to diagnose various conditions, including:

  • Autoimmune hemolytic anemia
  • Hemolytic disease of the newborn
  • Blood transfusion reactions
  • Drug-induced hemolytic anemia It works by adding an anti-human globulin reagent to the blood sample, which causes agglutination (clumping) of red blood cells if antibodies are present.

Recent Guidelines and Recommendations

According to the most recent guidelines, the Coombs test should be considered in specific patient populations, such as those with chronic lymphocytic leukemia, non-Hodgkin lymphoma, and in patients with a history of autoimmune disease 1. This recommendation is based on the importance of identifying and managing anemia in these patients, as anemia can have a negative impact on quality of life and overall survival.

Key Points to Consider

  • The Coombs test is a valuable diagnostic tool in the evaluation of anemia and hemolysis.
  • It should be considered in patients with specific conditions, such as chronic lymphocytic leukemia and non-Hodgkin lymphoma.
  • The test results can help guide appropriate treatment decisions and improve patient outcomes.
  • Recent guidelines emphasize the importance of considering the Coombs test in the diagnostic workup of patients with anemia and hemolysis, as seen in the updated recommendations from 2021 1.

From the Research

Definition and Purpose of the COOMBS Test

  • The COOMBS test, also known as the direct antiglobulin test, is a diagnostic tool used to detect immune-related hemolytic anemia 2, 3, 4, 5.
  • It allows for the distinction between immune-related and nonimmune acquired hemolytic anemia, and is considered a crucial test in the diagnosis of autoimmune hemolytic anemia (AIHA) 2, 4, 5.

Mechanism and Interpretation of the COOMBS Test

  • The test detects the presence of immunoglobulin (Ig) G molecules on erythrocytes (RBC-IgG) 2, 3.
  • A positive COOMBS test indicates that the red blood cells are coated with antibodies or complement, which can lead to their destruction 3, 4.
  • A negative COOMBS test does not necessarily rule out AIHA, as there may be cases where the test is negative due to low levels of IgG sensitization or other factors 3.

Clinical Applications and Limitations of the COOMBS Test

  • The COOMBS test is used to diagnose and subclassify AIHA, and to distinguish it from other types of hemolytic anemia 4, 5.
  • The test has limitations, such as the potential for false-negative results, and may require additional testing to confirm the diagnosis 3, 5.
  • Advanced testing, such as flow cytometry or radioimmunoassay, may be necessary to detect low levels of IgG sensitization or to identify rare causes of hemolytic anemia 2, 3.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Progress in diagnosis and treatment of autoimmune hemolytic disorders].

[Rinsho ketsueki] The Japanese journal of clinical hematology, 2017

Research

Autoimmune Hemolytic Anemia: Diagnosis and Differential Diagnosis.

Hematology/oncology clinics of North America, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.